Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in
combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy
(when applicable). As well as to evaluate the following efficacy parameters: Progression-free
survival (PFS), objective response rate (proportion of patients with complete response [CR]
plus partial response [PR]), overall survival (OS), duration of response (DOR), time to
progression (TTP).